Ipsen, a French biopharmaceutical company specializing in specialty care, and Biomunex have forged an exclusive global licensing agreement for a pioneering MAIT cell engager in the field of immuno-oncology.
Under this agreement, Ipsen gains exclusive global rights to develop, produce, and market BMX-502. This is an innovative, pre-clinical T cell engager with first-in-class potential. BMX-502 functions as a bispecific antibody, engaging MAIT cells—a unique subset of non-conventional T cells—and targets the clinically validated tumor antigen GPC3 to effectively annihilate cancer cells.
According to the terms outlined, Biomunex will complete the IND-enabling package. Ipsen will then be responsible for preparing for Phase I activities, which includes submitting the Investigational New Drug (IND) application, along with overseeing all ensuing clinical development and worldwide commercialization efforts.
Biomunex stands to receive as much as $610 million, composed of upfront payments and additional compensation contingent upon achieving successful development, regulatory, and commercial milestones. Furthermore, they will earn tiered global royalties based on sales.
